-
Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy
-
Yongxian Hu, Jiasheng Wang, Chengfei Pu, Kui Zhao, Qu Cui, Guoqing Wei, Wenjun Wu, Lei Xiao, Yang Xiao, Jinping Wang, Zhao Wu, He Huang
-
Cancer Res Treat. 2018;50(4):1462-1466. Published online February 5, 2018
-
DOI: https://doi.org/10.4143/crt.2017.473
-
-
 Abstract
 PDF PubReader ePub
- Chimeric antigen receptor T-cell strategy targeting CD19 (CART19) has prominent anti-tumor effect for relapsed/refractory B-cell lymphomas. CART19-associated complications have been gradually recognized, however, late-onset complications have not been extensively studied. Herein, for the first time we report a diffuse large B-cell lymphoma patient with terminal ileum involvement obtained rapid remission and developed spontaneous terminal ileal perforation 38 days following CART19 infusion. The late-onset perforation reminds us that, for the safety of CART treatment, more cautions are warranted for the management of delayed GI complications.
-
Citations
Citations to this article as recorded by  - Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma
Maria T. Kuipers, Anne M. Spanjaart, Francesca Bonifazi, Roberta diBlasi, Pier L. Zinzani, Catherine Thieblemont, Mathilde Baudet, Bart J. Biemond, Wouter E. M. Kok, Marie J. Kersten
Leukemia & Lymphoma.2024; 65(3): 399. CrossRef - Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas
Egesta Lopci, Michel Meignan
PET Clinics.2020; 15(1): 23. CrossRef - CAR-T cells: the Chinese experience
Linqin Wang, Elaine Tan Su Yin, Houli Zhao, Fang Ni, Yongxian Hu, He Huang
Expert Opinion on Biological Therapy.2020; 20(11): 1293. CrossRef - Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma
Zuyu Liang, Hao Zhang, Mi Shao, Qu Cui, Zhao Wu, Lei Xiao, He Huang, Yongxian Hu
Medicine.2020; 99(43): e22510. CrossRef - PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
Marcus Unterrainer, Michael Ruzicka, Matthias P. Fabritius, Lena M. Mittlmeier, Michael Winkelmann, Johannes Rübenthaler, Matthias Brendel, Marion Subklewe, Michael von Bergwelt-Baildon, Jens Ricke, Wolfgang G. Kunz, Clemens C. Cyran
European Radiology Experimental.2020;[Epub] CrossRef - A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang
Frontiers of Medicine.2020; 14(6): 711. CrossRef - Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy
Aiyun Jin, Jingjing Feng, Zhudan Wang, Li Jiang, Yongxian Hu, Kui Zhao, He Huang
Bone Marrow Transplantation.2019; 54(7): 969. CrossRef
-
7,570
View
-
250
Download
-
8
Web of Science
-
7
Crossref
|
KCA
